HC Wainwright starts off coverage on Blueprint Medicines (NASDAQ:BPMC) with a Buy rating.
The firm’s price target of $100 reps 37% upside
for shares, but still stands below the 52-week high for Blueprint of
$102.98 and consensus sell-side PT of $109.58.
https://seekingalpha.com/news/3503667-hc-wainwright-joins-bull-party-blueprint-medicines
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.